Physician profile
Lynne E Wagoner
NPI 1831147099
$88,073.06
in general payments reported to CMS, 2019-2025
28 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $18K · 2021: $14K · 2022: $15K · 2023: $15K · 2024: $9,879 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $1,293 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,105.00 |
| Food and Beverage | $1,293.44 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35,459.15 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $21,658.74 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $12,897.34 | 2019-2021 | |
| Pfizer INC. | $11,550.91 | 2019-2023 | |
| Lilly USA, LLC | $4,545.00 | 2020-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $484.99 | 2019-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $416.45 | 2020-2024 | Cardiomems |
| Janssen Pharmaceuticals, INC | $171.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $167.95 | 2022-2025 | Winrevair, Verquvo |
| Amgen INC. | $108.05 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $91.31 | 2020-2021 | |
| Amarin Pharma, INC. | $75.57 | 2019-2022 | |
| Akcea Therapeutics, INC. | $60.49 | 2020-2021 | |
| United Therapeutics Corporation | $46.22 | 2021 | |
| Vifor Pharma, INC. | $39.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $36.49 | 2019 | |
| Boston Scientific Corporation | $36.32 | 2020 | |
| Baxter Healthcare | $35.88 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Lundbeck LLC | $31.11 | 2019 | |
| Cvrx, INC. | $30.12 | 2022-2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $26.87 | 2022-2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $22.85 | 2019-2022 | |
| Medtronic, INC. | $17.30 | 2022 | |
| Impulse Dynamics (USA) INC. | $17.13 | 2024 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $15.91 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.66 | 2024 | Lifevest |
| Bardy Diagnostics, INC. | $15.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynne Wagoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.